How the answers frame Eli Lilly
This snapshot covers 250 benchmark questions put to ChatGPT, Claude, Gemini, Perplexity and Grok on 2026-09-29, or 1,250 answers in all. Eli Lilly was named in 155 of them. Grok named it most often (45 of 250). The other four assistants were close to one another, between 26 and 29 each.
The pattern by question type is uneven. Lilly showed up most on leadership questions (35% of those answers) and less on employer (19%), coverage and access (18%), innovation (16%) and pricing transparency (15%). It was nearly absent from service (0%) and thin on reliability, value and safety (5% each).
In the stored answers, Lilly's role changes with the question. In Gemini's answer on new-drug track records, it led the list, credited with the approval of Foundayo (orforglipron), described as an oral GLP-1 for weight management. Perplexity used Lilly's Mounjaro versus Trulicity trial as the main example for diabetes cardiovascular outcomes, but stressed that the result was a within-company comparison. On insulin, Perplexity named Lilly among the makers that announced voluntary list-price cuts and among those offering some options capped at $35 a month. ChatGPT listed it among insulin producers in a question about criticism over price increases on older medicines. Grok described Lilly as consistently high across employer sources, citing BioSpace and Glassdoor lists.
The credited-for tags are small and mostly uninformative: 'Not Substantive' (5), 'Price & Value' (3), 'Financial Performance' (2) and 'Labour & Workplace' (1). Most Lilly mentions were list placements, not extended descriptions.
Among 15 sector peers, Lilly ranks sixth on answer appearances in this snapshot. Johnson & Johnson (192), UnitedHealth Group (179), CVS Health and Pfizer (174 each) and Merck (158) were named more often.
…cut list prices for Humalog and Humulin by 70% and reduced the price of unbranded insulin Lispro.
What the press is saying
The PeakMetrics news index logged 19,681 mentions of Lilly over the last 30 days, 2,353 with the brand in the headline. That is in the same range as Merck (20,731), Amgen (20,317) and Pfizer (19,027).
The recent headlines mix several storylines. Trade and market outlets reported an FDA nod for the once-weekly basal insulin Onswik and Lilly's $2.9 billion purchase of Merida Biosciences to strengthen its immunology pipeline. Investor coverage noted two billionaire investors buying Lilly stock. A pipeline report on non-Hodgkin lymphoma listed Lilly among several companies. One widely syndicated story concerned a missing Lilly executive and an arrest in that case.
…the reported advantage is a within-company comparison, not proof it beats competing manufacturers’ drugs.
The gap
Insulin is the clearest overlap. The press headline is a new insulin approval, while the assistants tie Lilly to insulin through list-price cuts and capped out-of-pocket options. The two are about the same product area but tell different stories.
Other press storylines did not appear in the stored answers we were given. These include the Merida deal, investor buying, and the missing-executive case. That is a sample of 13 of the 155 answers, so this is not proof they are absent from the rest.
Volume also differs by peer. Amgen has news volume close to Lilly's but was named in only 69 answers, and Lilly's 155 answer appearances sit behind five peers with similar or lower news counts. Press volume and AI visibility measure different things here.
Consistently high across sources for respect, benefits, work-life balance, mentorship/career growth, inclusive culture, and meaningful work tied to patient outcomes.
What to watch
A comms team for Lilly would read this as a snapshot from live answers, not a ranking. Answer text varies between runs, so single figures should not be read as movement.
Three things stand out. First, leadership and innovation questions carry Lilly's visibility, while safety, reliability and value questions carry very little. Second, price framing appears in both directions: as a voluntary cut in Perplexity's insulin answer and as a name in ChatGPT's answer about price criticism. Third, Grok, which named Lilly most often, drew on employer rankings that the other assistants' sampled answers did not mention.
The next step would be to check which cited domains sit behind the insulin, pipeline and employer answers, since those sources shape what the assistants repeat.